From Pills to Cures: Fall 2022 Kickoff

On September 8, MBG invited Dr. Samarth Kulkarni, CEO of CRISPR Therapeutics, to recount the evolution of CRISPR from its early days, through the clinical stage, and towards the commercialization of a new class of curative medicines. In this event, around 200 MIT students and affiliates had the opportunity to learn from an industry leader about the history and potential of CRISPR-based medicine.